Tirzepatide – 30 mg
Tirzepatide – 30 mg Tirzepatide is a once-weekly prescription injection (sold as Mounjaro or Zepbound) used for type 2 diabetes and chronic weight management. It acts as a GIP and GLP-1 receptor agonist to reduce appetite, increase fullness, and control blood sugar. FDA-approved dosages range from 2.5 mg to 15 mg weekly; 30 mg is not a recognized, standard, or approved therapeutic dose.
Research Use Only Disclaimer
FOR RESEARCH USE ONLY This product is not intended for human or animal use.Not for medical, clinical, diagnostic, therapeutic, metabolic, endocrine, dosing, or consumption purposes.No dosage, administration, or biological outcome claims are made or implied.Use is restricted to qualified laboratory research environments only.
❓Frequently Asked Questions
Is tirzepatide approved for clinical or weight-related use?
No. This peptide is supplied strictly for laboratory research purposes.
Does this product include a Certificate of Analysis (COA)?
Yes. Every batch includes a third-party verified COA.
Why is tirzepatide supplied in a 30 mg research format?
Higher-mass quantities support extended analytical testing, repeat experimentation, and long-term reference evaluation, not application or use.
Can this compound be used in humans or animals?
No. It is not approved for use in living systems.
How is this product classified?
It is classified solely as a research peptide, not a drug, supplement, or therapeutic agent.